1440 - PD-L1 testing for access to pembrolizumab in treatment na´ve patients with locally advanced or metastatic non-small cell lung cancer

Page last updated: 22 June 2017

Application Detail

Status

Open

Description of Medical Service

ImmunoHistoChemistry test for evaluation of Programmed Cell Death Ligand 1 (PD-L1) expression to determine eligibility for treatment with pembrolizumab

Description of Medical Condition

Locally advanced or metastatic non-small cell lung cancer

Reason for Application

New MBS item

Medical Service Type

Investigative

Previous Application Number

Not Applicable

Associated Documentation

Application Form

-

PICO Confirmation

Final Protocol (PDF 522 KB)
Final Protocol (Word 692 KB)

Assessment Report

-

Public Summary Document

Public Summary Document (PDF 240 KB)
Public Summary Document (Word 98 KB)

Meetings for this Application

PASC

11 - 12 August 2016

ESC

7 - 8 February 2017

MSAC

6 - 7 April 2017